Organovo Holdings Inc. products

Architecture of ExVive™ 3D Bioprinted Human Liver Tissue with distinct hepatocellular (HC) and non-parenchymal cell (NPC) compartments.  The automated bioprinting process results in scalable tissues, with tight control of the composition and geometry.

Our bioprinting process starts with the identification of key architectural and compositional elements of a target tissue, and the creation of a design that can be utilized by a bioprinter to generate that tissue in the laboratory environment. The next step is to develop the bioprocess protocols required to generate the multi-cellular building blocks – also called bio-ink – from the cells that will be used to build the target tissue. While the bioprinting process is cell-agnostic, our bioprinted tissues utilize primary human cells where possible in order to produce the in vivo-like physiology most relevant for drug testing. We utilize multiple independent sources for our input cells to allow patient selection and high levels of diversity.

We will apply our bioprinting expertise where it is applicable, but we fully intend to utilize the absolute best technology available to attack a given disease tissue.  It is our belief that crafting the right model is of the utmost importance and so we will harness the power of any technology we can find to achieve that goal.